Barclays Downgrades UCB (OTCMKTS:UCBJY) to Hold

UCB (OTCMKTS:UCBJY) was downgraded by analysts at Barclays from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

UCBJY has been the topic of a number of other research reports. Wolfe Research raised shares of UCB to a “strong-buy” rating in a report on Monday, February 23rd. Zacks Research cut UCB from a “hold” rating to a “strong sell” rating in a research report on Thursday, June 11th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

UCB Price Performance

OTCMKTS UCBJY opened at $150.09 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. UCB has a one year low of $89.00 and a one year high of $168.76. The company has a 50-day simple moving average of $145.71 and a 200-day simple moving average of $147.35.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.